

# Completed Clinical Trial Data (2002-2009)

- ❑ **Trial conducted on Stage IV patients. Average life expectancy at time of treatment was 3-5 months.**

- ❑ **Melanoma - US FDA IND 8851**

- ❑ Phase I (10 patients)
- ❑ Efficacy – Average survival of 9/10 patients was 198 days. One patient is still alive today with no evidence of disease. February 21, 2013 was 11 years since her first vaccination.
- ❑ Phase II (15 patients)
- ❑ Efficacy - The average survival of the 10 deceased patients was 590 days. At 5 years, 5 patients were still alive, with no evidence of disease.

- ❑ **Renal Cell Carcinoma - US FDA IND 9519**

- ❑ Phase I (10 patients)
- ❑ Efficacy – Average survival of the first 6 deceased patients in the Phase I trial was 274 days with 3 patients living greater than 18 months and one patient still alive with no evidence of disease at 2 years.

- ❑ **Neuroblastoma - US FDA IND 13103**

- ❑ Phase I (1 patient)
- ❑ Efficacy – The patient initially presented in a wheelchair and had no bowel or bladder control requiring indwelling catheters. Within 1 month of her initial vaccine, she was able to regain her ability to walk and have the catheters removed. She went on to dance and return to work for 8 months and lived a total of 18 months after her initial vaccine treatment

- ❑ **14% of patients treated remain disease free (longest long term disease free patient has remained so for 11+ years to date).**

- ❑ **Average life span of all patients, post-therapy is 3 years.**